Note 12 - Segments - Operating Income by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Rental, fees and other income	$ 4,790,061	$ 4,121,491
Property and related expenses	(1,563,577)	(1,574,990)
General and administrative expenses	(2,084,450)	(1,964,620)
Depreciation and amortization	(1,351,018)	(1,333,574)
Interest expense	(1,515,206)	(867,767)
Loss on Conduit Pharmaceuticals marketable securities	(3,861,233)	0
Gain on deconsolidation of SPAC	0	0
Other income, net	4,646	742,117
Income tax expense	(79,565)	(148,453)
Gain on sale of real estate	2,018,095	417,337
Net loss	(3,737,795)	(608,459)
Conduit Pharmaceuticals Inc [Member]
Loss on Conduit Pharmaceuticals marketable securities	(3,861,233)	0
Operating Segments [Member]
Net operating income, as defined	3,130,936	2,546,501
Office/Industrial Properties [Member] | Operating Segments [Member]
Rental, fees and other income	2,967,720	2,861,998
Property and related expenses	(1,382,393)	(1,460,690)
Net operating income, as defined	1,585,327	1,401,308
Model Home Properties [Member] | Operating Segments [Member]
Rental, fees and other income	1,268,953	855,120
Property and related expenses	(136,778)	(30,996)
Net operating income, as defined	1,132,175	824,124
Retail Properties [Member] | Operating Segments [Member]
Rental, fees and other income	553,388	458,867
Property and related expenses	(139,954)	(137,798)
Net operating income, as defined	$ 413,434	$ 321,069